Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948088 · ClinicalTrials.gov registry record
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
A clinical trial of Giant Cell Tumors, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 183
- Enrollment target
- 15
- Study locations
NCT02948088: Completed study of Giant Cell Tumors, sponsored by Daiichi Sankyo.
NCT02948088 is a study of Giant Cell Tumors that has completed, run by Daiichi Sankyo. The registered enrollment target is 183 participants. The trial reports 15 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02948088, a study of Giant Cell Tumors, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 183 participants
- Enrollment target
- 15
- Study locations
Study Summary
TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of d-TGCT. This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.
Primary Outcome
The management plan received among the patients was collected from information routinely recorded in the patient files / medical records.
Conditions Studied
Study Locations (15)
Other
- Medizinische Universität Graz - Graz
- CHU Nantes - Nantes
- Westdeutsches Tumorzentrum - Essen
- Istituto Ortopedico Rizzoli - Bologna
- Istituto Nazionale Tumori-Foundazione IRCCS - Milan
- Leiden University Medical Center - Leiden
- Radboud universitair medisch centrum - Nijmegen
- Hospital Sant Pau - Barcelona
- Hospital Universitario Virgen del Rocio - Seville
- The Royal Marsden Hospital - London
- Nuffield Orthopaedic Centre - Oxford
California
- David Geffen School of Medicine at UCLA - Los Angeles
- University of California San Francisco - San Francisco
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2021-03-11 |
What the finished NCT02948088 record still lists
NCT02948088 is an observational study that tracks outcomes without assigning an intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Giant Cell Tumors appearing as the primary indexed condition, and to 0 interventions.
NCT02948088 lists 15 locations in 4 states (Other, California, New York).
Frequently Asked Questions
What is clinical trial NCT02948088 about?
NCT02948088 is a clinical study titled "Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project". TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pai...
What is the current status of trial NCT02948088?
This trial is currently completed. The enrollment target is 183 participants. The study started on 2016-11-18. Estimated completion is 2021-03-11.
What conditions does trial NCT02948088 study?
This clinical trial studies the following conditions: Giant Cell Tumors.
Who is sponsoring clinical trial NCT02948088?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02948088 being conducted?
This trial has 15 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI